Argenica Therapeutics (AGN) Stock Price, News & Analysis

Company Overview

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Insurance
• Current Symbol: ASX:AGN
• CUSIP: N/A
• CIK: N/A
• Web: argenica.com.au
• Phone: 61 8 9329 3396
• Fax: N/A
• Employees: 22,300
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,480,000.00
• Net Margins: -210.92%
• Pretax Margin: N/A
• Return on Equity: -50.70%
• Return on Assets: -27.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.75
• Quick Ratio: 12.21

Sales & Book Value

• Annual Sales: $2.60 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.11 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 128,090,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.79